Association Between IL-5 Levels and the Clinicopathologic Features of Eosinophilic Granulomatosis With Polyangiitis
- 2 February 2021
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 96 (5), 226-229
- https://doi.org/10.1212/wnl.0000000000011142
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCANeurology, 2020
- Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA statusNature Communications, 2019
- Update on eosinophilic granulomatosis with polyangiitisAllergology International, 2019
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisThe New England Journal of Medicine, 2017
- Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): Clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohortArthritis & Rheumatism, 2012
- Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patientsRheumatology, 2012
- Treatment of Patients with the Hypereosinophilic Syndrome with MepolizumabThe New England Journal of Medicine, 2008